Figure 2
From: Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
Cell survival of CBL Mts after treatment with MET inhibitors. A549 CBL isogenic cells with empty vector (EV) or CBL wild-type (WT) and mutations (SH: S80N/H94Y, Q: Q249E, V: V391I, W*: W802*). MET inhibitor SU11274 was treated 1 μM for 48 hr. CBL Mts showed more sensitivity to SU11274 treatment than CBL WT.
